News

GSK’s Priorix MMR vaccine received the federal agency’s approval which was based from data of 6 clinical trials evaluating its safety.

Impairment of cognitive function is a growing, concerning effect of "long COVID."

Adults living with HIV were more likely to have a breakthrough COVID-19 infection after vaccination, suggesting a need for additional vaccine doses in this population.

People infected with HIV are at a 4.5- to 12.9-fold increased risk of meningococcal disease compared to an otherwise healthy population, the study authors said.

Patients who took RBX2660 following antibiotic therapy had lower rates of recurrence and double the time to recurrence, compared to patients taking placebo.

There are now over 25 monkeypox infections confirmed in 12 US states and DC. There are an estimated 900 cases worldwide.

The advisory group is meeting on Tuesday to discuss the vaccine’s presenting data and a potential authorization.

New vaccine for COVID-19 employing receptor-binding domain-dimer-based platform achieves 87.6% efficacy against severe to critical illness.

The study authors determined that COVID-19 patients with HIV were 38% more likely to die than those without HIV.

Although underutilized, this highly efficacious vaccine can help prevent numerous cancers including the most prevalent—head and neck and cervical cancers.

The microbiota-based live therapeutic had a 68.3% success rate when administered following antibiotic treatment, versus a 55% success rate in a placebo group.

New research in Israel offers hope that multisystem inflammatory syndrome in children—a serious complication of COVID-19—declined during the Omicron surge of the pandemic.

In 2020, COVID-19 mortality rates were 5 times higher among adults in low socioeconomic positions.

The FDA and other health agencies are investigating fresh organic strawberries, branded as FreshKampo or HEB, that are believed to be the source of hepatitis A infections in the US and Canada.

Community transmission of monkeypox outside traditional endemic regions of the virus prompts calls for increased vigilance.

At a media briefing this morning, Infectious Diseases Society of America (IDSA) experts discussed the worldwide 600 confirmed cases of monkeypox.

Synairgen's inhalable Interferon-beta treatment, SNG001, may be a treatment option for hospitalized and immunocompromised COVID-19 patients.

The organization is behind community-based funding and educational programs to propel a healthier society at a grassroots level.

A clinician discusses the disease burden of reoccurring CDI, but sees a silver lining in the new investigational therapies potentially changing the treatment paradigm for the better.

Although this patient had none of these common risk factors associated with Candida empyema, she did have other factors predisposing her to fungal colonization and subsequent infection.

Medical professionals discuss how they affect immunity as well as the necessity of these additional vaccinations.

Four lessons learned from the AIDS crisis that can be applied to the fight against our current pandemic.

Conflicting priorities of infection control, antimicrobial stewardship, and critical care make the management of sepsis secondary to SARS-CoV-2 infection challenging.

With few exceptions, COVID-19 therapies have not been studied comparatively, so choosing therapies to preferentially recommend is difficult and is done, instead, by strength of evidence and quality of data.

A clinician is advocating for incorporating diagnostic stewardship practices within antimicrobial stewardship programs, which could someday lead to best practice guidelines on a larger scale.

Available literature on thrombosis occurrence in COVID-19 patients focuses on hospitalized cases. A new study sheds light on the incidence of thromboembolism in less severe cases of disease,

Utilizing a newer technology, investigators wanted to see if a reduction in time led to clinically significant antimicrobial adjustments.

A multicenter study looked at treating these infections with omadacycline.